These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 27009237

  • 1. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
    Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M.
    Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
    [Abstract] [Full Text] [Related]

  • 2. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P.
    Neuro Oncol; 2018 Oct 09; 20(11):1462-1474. PubMed ID: 29939339
    [Abstract] [Full Text] [Related]

  • 3. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
    Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE.
    Cell Death Differ; 2010 Mar 09; 17(3):499-512. PubMed ID: 19834490
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A, Mansouri K, Alemzadeh G, Safa M, Rastaghi AE, Asghari SM.
    Biochim Biophys Acta Gen Subj; 2018 Dec 09; 1862(12):2688-2700. PubMed ID: 30251659
    [Abstract] [Full Text] [Related]

  • 5. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M.
    Hepatology; 2014 Oct 09; 60(4):1264-77. PubMed ID: 24849467
    [Abstract] [Full Text] [Related]

  • 6. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades.
    Lee JH, Choi S, Lee Y, Lee HJ, Kim KH, Ahn KS, Bae H, Lee HJ, Lee EO, Ahn KS, Ryu SY, Lü J, Kim SH.
    Mol Cancer Ther; 2010 Feb 09; 9(2):389-99. PubMed ID: 20103598
    [Abstract] [Full Text] [Related]

  • 7. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells.
    Mac Gabhann F, Popel AS.
    Am J Physiol Heart Circ Physiol; 2004 Jan 09; 286(1):H153-64. PubMed ID: 12714333
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D.
    Oncogene; 2005 Dec 01; 24(54):8025-37. PubMed ID: 16116481
    [Abstract] [Full Text] [Related]

  • 9. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
    Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J.
    Cell Cycle; 2008 Aug 15; 7(16):2553-61. PubMed ID: 18719373
    [Abstract] [Full Text] [Related]

  • 10. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
    Zhang Q, Yu C, Peng S, Xu H, Wright E, Zhang X, Huo X, Cheng E, Pham TH, Asanuma K, Hatanpaa KJ, Rezai D, Wang DH, Sarode V, Melton S, Genta RM, Spechler SJ, Souza RF.
    Gastroenterology; 2014 Feb 15; 146(2):461-72.e6. PubMed ID: 24120473
    [Abstract] [Full Text] [Related]

  • 11. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Oncotarget; 2016 Sep 27; 7(39):63124-63137. PubMed ID: 27517319
    [Abstract] [Full Text] [Related]

  • 12. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.
    Eur J Cancer; 2011 Oct 27; 47(15):2353-63. PubMed ID: 21680174
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
    Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S.
    PLoS Med; 2007 Jun 27; 4(6):e186. PubMed ID: 17550303
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 27; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 15. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
    Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Bartek J, Fischer W, Lukas J, Rich JN, Bartek J.
    J Exp Med; 2012 Mar 12; 209(3):507-20. PubMed ID: 22393126
    [Abstract] [Full Text] [Related]

  • 16. Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma.
    Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ando T, Schwartz HS, Schoenecker JG.
    Mol Cancer Res; 2014 Aug 12; 12(8):1100-11. PubMed ID: 24759089
    [Abstract] [Full Text] [Related]

  • 17. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK, Piao Y, de Groot JF.
    Clin Cancer Res; 2009 Jul 15; 15(14):4589-99. PubMed ID: 19567589
    [Abstract] [Full Text] [Related]

  • 18. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
    D'Alessio A, Proietti G, Lama G, Biamonte F, Lauriola L, Moscato U, Vescovi A, Mangiola A, Angelucci C, Sica G.
    Oncotarget; 2016 Nov 29; 7(48):78541-78556. PubMed ID: 27705944
    [Abstract] [Full Text] [Related]

  • 19. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF.
    Neuro Oncol; 2016 Sep 29; 18(9):1230-41. PubMed ID: 26965451
    [Abstract] [Full Text] [Related]

  • 20. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
    Farzaneh Behelgardi M, Zahri S, Gholami Shahvir Z, Mashayekhi F, Mirzanejad L, Asghari SM.
    Mol Biol Rep; 2020 Mar 29; 47(3):2061-2071. PubMed ID: 32072404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.